Nabi Biopharmaceuticals
12276 Wilkins Avenue
Rockville,
MD 20852
United States - Map
Phone: 301-770-3099
Fax: 301-770-3097
Web Site: http://www.nabi.com
| Nabi Biopharmaceuticals, a biopharmaceutical company, develops products that address unmet medical needs in the areas of nicotine addiction and infectious disease in the United States. The company is developing NicVAX, a proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. It has a manufacturing services agreement with Biotest Pharmaceuticals Corporation, which enables it to obtain clinical lots of its retained products, as well as component products from Biotest. Nabi Biopharmaceuticals also has license and royalty agreements with National Institute of Allergy and Infectious Diseases; National Institute for Drug Abuse; Department of Defense; National Institutes of Health; and University of Maryland. The company was founded in 1967 and is headquartered in Rockville, Maryland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Raafat Fahim Ph.D., 55
Chief Exec. Officer, Pres, Acting Chief Financial Officer |
N/A
| N/A | Dr. Paul Kessler M.D., 54
Chief Medical Officer and Sr. VP of Clinical, Medical & Regulatory Affairs |
$
455.00K | N/A | Dr. Matthew W. Kalnik Ph.D.,
Sr. VP of Strategic Planning & Bus. Operations |
N/A
| N/A | Mr. Ronald B. Kocak , 51
Chief Accounting Officer and Controller |
N/A
| N/A | Mr. Constantine Alexander ,
Sec. |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.22% Nasdaq 
Profile
